Zobrazeno 1 - 10
of 39
pro vyhledávání: '"Jan W Mulder"'
Autor:
Hans L. Zaaijer, Roeland Zoutendijk, Annemiek A. van der Eijk, Clemens Richter, Jan W. Mulder, Harry L.A. Janssen, Marchina E. van der Ende, Jurriën G.P. Reijnders, Milan J. Sonneveld, Robert A. de Man, Frank P. Kroon, Bettina E. Hansen, Theodora E. M. S. de Vries-Sluijs
Publikováno v:
Journal of Infectious Diseases, 206(6), 974-980. Oxford University Press
Journal of infectious diseases, 206(6), 974-980. Oxford University Press
Journal of infectious diseases, 206(6), 974-980. Oxford University Press
Background.The kinetics of hepatitis B surface antigen (HBsAg) are predictive in HBV-infected patients treated with pegylated interferon. Knowledge about the value of HBsAg levels in patients coinfected with HBV and human immunodeficiency virus (HIV)
Autor:
Rob ter Heine, Jan W. Mulder, Alwin D. R. Huitema, Jiri F. P. Wagenaar, Eric C. M. van Gorp, Jos H. Beijnen
Publikováno v:
British Journal of Clinical Pharmacology. 69:475-483
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • The combination of raltegravir, etravirine and ritonavir boosted darunavir is a potent antiretroviral regimen for patients who have been heavily pre-treated for HIV-infection. All these agents have to exer
Autor:
Martin Schutten, Marchina E. van der Ende, Jurriën G.P. Reijnders, Andy I. M. Hoepelman, Theodora E. M. S. de Vries-Sluijs, Harry L.A. Janssen, Jan W. Mulder, Suzan D. Pas, Robert A. de Man, Clemens Richter, Hans L. Zaaijer, Bettina E. Hansen, Jan M. Prins
Publikováno v:
Gastroenterology, 139(6), 1934-1941. W.B. Saunders Ltd
Gastroenterology, 139(6), 1934-1941. W.B. Saunders
Gastroenterology, 139(6), 1934-1941. W.B. Saunders
BACKGROUND & AIMS: We investigated the long-term efficacy and renal safety of tenofovir disoproxil fumarate (TDF), administered to patients co-infected with human immunodeficiency virus and hepatitis B virus (HBV) as part of an antiretroviral therapy
Autor:
Eric C. M. van Gorp, Jan W. Mulder, Martijn D. de Kruif, Eefje Jong, Hugo ten Cate, Susan Louw, Joost C. M. Meijers, Harry R. Büller
Publikováno v:
AIDS patient care and STDs, 23(12), 1001-1007. Mary Ann Liebert Inc.
The incidence of arterial and venous thrombosis in HIV-infected patients is increased compared to healthy controls. In this cross-sectional analysis we measured markers of endothelial cell activation, thrombin generation, fibrinolysis and anticoagula
Autor:
Davy A P Rockx, Jan W. Mulder, Eric C. M. van Gorp, Sandra A. W. M. Verkuijlen, Servi J. C. Stevens, Paul H M Smits, Jaap M. Middeldorp
Publikováno v:
AIDS, 21(16), 2141-9. Lippincott Williams and Wilkins
Stevens, S J C, Smits, P H M, Verkuijlen, S A W M, Rockx, D A P, van Gorp, E C M, Mulder, J W & Middeldorp, J M 2007, ' Aberrant Epstein-Barr virus persistence in HIV carriers is characterized by anti-Epstein-Barr virus IgA and high cellular viral loads with restricted transcription ', AIDS, vol. 21, no. 16, pp. 2141-9 . https://doi.org/10.1097/QAD.0b013e3282eeeba0
Stevens, S J C, Smits, P H M, Verkuijlen, S A W M, Rockx, D A P, van Gorp, E C M, Mulder, J W & Middeldorp, J M 2007, ' Aberrant Epstein-Barr virus persistence in HIV carriers is characterized by anti-Epstein-Barr virus IgA and high cellular viral loads with restricted transcription ', AIDS, vol. 21, no. 16, pp. 2141-9 . https://doi.org/10.1097/QAD.0b013e3282eeeba0
OBJECTIVE: Epstein-Barr virus (EBV)-positive lymphomas in HIV carriers are paralleled by elevated EBV-DNA loads in the circulation. Approximately 20% of asymptomatic HIV carriers also show elevated circulating EBV-DNA loads. We aimed to characterize
Autor:
Jan W. Mulder, Henry J. C. de Vries, Akke K. Van der Bij, Thomas A. Ruys, Katja C. Wolthers, Suzanne Jurriaans, Michiel A. van Agtmael, Roel A. Coutinho, Maria Prins, Sylvia M. Bruisten, Thijs J W van de Laar, Jan van der Meer, Kees Brinkman
Publikováno v:
Van De Laar, T J W, Van Der Bij, A K, Prins, M, Bruisten, S M, Brinkman, K, Ruys, T A, Van Der Meer, J T M, De Vries, H J C, Mulder, J W, Van Agtmael, M, Jurriaans, S, Wolthers, K C & Coutinho, R A 2007, ' Increase in HCV incidence among men who have sex with men in Amsterdam most likely caused by sexual transmission ', Journal of Infectious Diseases, vol. 196, no. 2, pp. 230-238 . https://doi.org/10.1086/518796
Journal of Infectious Diseases, 196(2), 230-238. Oxford University Press
Journal of infectious diseases, 196(2), 230-238. Oxford University Press
The Journal of Infectious Diseases, 196(2), 230-238. Oxford University Press
Journal of Infectious Diseases, 196(2), 230-238. Oxford University Press
Journal of infectious diseases, 196(2), 230-238. Oxford University Press
The Journal of Infectious Diseases, 196(2), 230-238. Oxford University Press
We retrospectively screened 1836 men who have sex with men (MSM) participating in the Amsterdam Cohort Studies (1984-2003) for hepatitis C virus (HCV) antibodies. HCV incidence was 0.18/100 person-years (PY) in human immunodeficiency virus (HIV)-posi
Autor:
Jan W. Mulder, Pieter L. Meenhorst, Eric C. M. van Gorp, Alwin D. R. Huitema, Bregt S. Kappelhoff, Jan M. Prins, Jos H. Beijnen, Sanjay U. C. Sankatsing
Publikováno v:
British journal of clinical pharmacology, 60(3), 276-286. Wiley-Blackwell
Aims The aim of the study was to characterize the population pharmacokinetics of indinavir, define the relationship between the pharmacokinetics of indinavir and ritonavir, and to identify the factors influencing the pharmacokinetics of indinavir alo
Autor:
Jan M. Prins, Alwin D. R. Huitema, Zeynep Yalvaç, Pieter L. Meenhorst, Jan W. Mulder, Bregt S. Kappelhoff, Jos H. Beijnen
Publikováno v:
Clinical pharmacokinetics. 44(8):849-861
Objective: The aim of this study was to characterise the population pharmacokinetics of efavirenz in a representative patient population and to identify patient characteristics influencing the pharmacokinetics of efavirenz, with the ultimate goal of
Autor:
G Corine Ekhart, Jan W. Mulder, Jos H. Beijnen, Monique M R de Maat, Alwin D. R. Huitema, Cornelis H. W. Koks
Publikováno v:
Clinical Pharmacokinetics. 42:223-282
HIV-infected individuals usually receive a wide variety of drugs in addition to their antiretroviral drug regimen. Since both non-nucleoside reverse transcriptase inhibitors and protease inhibitors are extensively metabolised by the cytochrome P450 s
Autor:
Jan W. Mulder, Albert T. A. Mairuhu, Eric C. M. van Gorp, Pieter L. Meenhorst, Jos H. Beijnen, Alwin D. R. Huitema, Monique M R de Maat
Publikováno v:
Therapeutic Drug Monitoring, 25, 3, pp. 367-73
Therapeutic Drug Monitoring, 25, 367-73
Therapeutic Drug Monitoring, 25, 367-73
Item does not contain fulltext The objective of this study was to evaluate plasma concentrations of nonnucleoside reverse transcriptase inhibitors (NNRTIs) and protease inhibitors (PIs) within several dosing schemes in a cohort of HIV-infected patien